Literature DB >> 7933109

Interaction of papillomaviruses with the cell surface.

R B Roden1, R Kirnbauer, A B Jenson, D R Lowy, J T Schiller.   

Abstract

To initiate an investigation of the initial step in papillomavirus infection, we have examined the interaction of bovine papillomavirus type 1 (BPV) virions with C127 cells by two assays, binding of radioiodinated BPV virions to cell monolayers and BPV-induced focal transformation. Under physiological conditions, the labeled virions bound to the cell surface in a dose-dependent manner within 1 h. Antibody studies indicated that the interaction was specific and related to infectivity: polyclonal sera raised to BPV virions or to baculovirus-expressed BPV L1 virus-like particles (VLPs) inhibited BPV binding and focal transformation, while sera to denatured BPV virions, to denatured BPV L1, or to human papillomavirus type 16 (HPV-16) VLPs were not inhibitory. An exception was that antisera to BPV L2 were neutralizing but did not inhibit binding. Unlabeled BPV virions and BPV VLPs competed with binding to the cell surface in a concentration-dependent manner. Binding to the cell surface appeared to depend primarily on L1, since BPV VLPs composed of L1 alone or of L1/L2 were equally effective in inhibiting binding and focal transformation. VLPs of HPV-16 also inhibited BPV binding and BPV transformation of C127 cells, suggesting that they interact with the same cell surface molecule(s) as BPV virions. Radiolabeled BPV bound specifically to several mammalian cell lines of fibroblastic and epithelial origin, as well as to a human schwannoma and melanoma lines, although some lines bound up to 10 times as many counts as others. Radiolabeled HPV-16 VLPs bound to both human keratinocytes and mouse C127 cells. The results suggest that papillomaviruses bind a widely expressed and evolutionarily conserved cell surface receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933109      PMCID: PMC237166     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Tissue site-specific enhancer function of the upstream regulatory region of human papillomavirus type 11 in cultured keratinocytes.

Authors:  B M Steinberg; K J Auborn; J L Brandsma; L B Taichman
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

Review 2.  Viral receptors of the immunoglobulin superfamily.

Authors:  J M White; D R Littman
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

3.  Attempted transmission of warts from man, cattle, and horses and of deer fibroma, to selected hosts.

Authors:  L D Koller; C Olson
Journal:  J Invest Dermatol       Date:  1972-06       Impact factor: 8.551

4.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

5.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

Authors:  S Ghim; N D Christensen; J W Kreider; A B Jenson
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

7.  In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.

Authors:  M S Barbosa; W C Vass; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

Review 8.  Prospects for cervical cancer vaccines.

Authors:  L Crawford
Journal:  Cancer Surv       Date:  1993

9.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

10.  Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans.

Authors:  M T Shieh; D WuDunn; R I Montgomery; J D Esko; P G Spear
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  55 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 6.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

7.  Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.

Authors:  Timothy D Culp; Lynn R Budgeon; M Peter Marinkovich; Guerrino Meneguzzi; Neil D Christensen
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.

Authors:  Nadine Kämper; Patricia M Day; Thorsten Nowak; Hans-Christoph Selinka; Luise Florin; Jan Bolscher; Lydia Hilbig; John T Schiller; Martin Sapp
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

9.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

10.  Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; F Breitburd; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.